Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Genelux Corp (GNLX)

Genelux Corp (GNLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 108,431
  • Shares Outstanding, K 44,806
  • Annual Sales, $ 10 K
  • Annual Income, $ -32,150 K
  • EBIT $ -33 M
  • EBITDA $ -33 M
  • 60-Month Beta 0.15
  • Price/Sales 12,881.72
  • Price/Cash Flow N/A
  • Price/Book 7.58

Options Overview Details

View History
  • Implied Volatility 775.48% (-11.35%)
  • Historical Volatility 70.47%
  • IV Percentile 92%
  • IV Rank 69.65%
  • IV High 1,095.90% on 12/10/25
  • IV Low 40.00% on 02/12/26
  • Expected Move (DTE 16) 0.60 (23.24%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 3
  • Volume Avg (30-Day) 18
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 575
  • Open Int (30-Day) 526
  • Expected Range 1.97 to 3.16

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.18
  • Number of Estimates 2
  • High Estimate $-0.17
  • Low Estimate $-0.19
  • Prior Year $-0.21
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.29 +11.79%
on 03/30/26
3.03 -15.37%
on 03/02/26
-0.42 (-14.09%)
since 02/27/26
3-Month
2.29 +11.79%
on 03/30/26
4.99 -48.68%
on 01/05/26
-1.80 (-41.28%)
since 12/31/25
52-Week
1.99 +28.81%
on 04/09/25
8.53 -69.99%
on 11/05/25
-0.04 (-1.54%)
since 04/01/25

Most Recent Stories

More News
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses...

GNLX : 2.56 (+5.79%)
Genelux Corporation to Participate in Upcoming Conferences

WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation ( NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the Company will participate in...

GNLX : 2.56 (+5.79%)
Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners

WESTLAKE VILLAGE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation ( NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...

GNLX : 2.56 (+5.79%)
Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock

WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten...

GNLX : 2.56 (+5.79%)
Genelux Corporation Announces Proposed Public Offering of Common Stock

WESTLAKE VILLAGE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced a...

GNLX : 2.56 (+5.79%)
Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials

-- Interim data from 14 patients with progressive lung cancers in dose-escalation cohorts of systemically administered Olvi-Vec-primed immunochemotherapy across ongoing SCLC and NSCLC trials; enrollment...

GNLX : 2.56 (+5.79%)
Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) --   Genelux Corporation ( NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten,...

GNLX : 2.56 (+5.79%)
Genelux Corporation to Participate in a Fireside Chat at Piper Sandler 37th Annual Healthcare Conference

WESTLAKE VILLAGE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation ( NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...

GNLX : 2.56 (+5.79%)
Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates

-- Lung cancer programs progressing with interim data updates expected in Q4 2025 -- -- Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected in the second half of 2026...

GNLX : 2.56 (+5.79%)
Genelux Corporation to Participate in a Fireside Chat at H.C. Wainwright Global Investment Conference

WESTLAKE VILLAGE, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, CEO...

GNLX : 2.56 (+5.79%)

Business Summary

Genelux Corporation is a clinical-stage biopharmaceutical company. It focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec, is a proprietary,...

See More

Key Turning Points

3rd Resistance Point 2.69
2nd Resistance Point 2.63
1st Resistance Point 2.60
Last Price 2.56
1st Support Level 2.50
2nd Support Level 2.44
3rd Support Level 2.41

See More

52-Week High 8.53
Fibonacci 61.8% 6.03
Fibonacci 50% 5.26
Fibonacci 38.2% 4.49
Last Price 2.56
52-Week Low 1.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.